Reuters logo
BRIEF-Corvus Pharmaceuticals announces interim results from its ongoing Phase 1/1b study
2017年6月5日 / 下午2点22分 / 5 个月内

BRIEF-Corvus Pharmaceuticals announces interim results from its ongoing Phase 1/1b study

June 5 (Reuters) - Corvus Pharmaceuticals Inc:

* Announces interim results demonstrating anti-tumor activity of CPI-444 in renal and lung cancer patients resistant or refractory to prior PD-(L)1 treatment

* Criteria met for second expansion of renal cell cancer cohort treated with combination therapy​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below